Grounding Value‐Based Drug Pricing in Population Health

The authors argue that the term “value-based pricing” should be restricted to arrangements where drugs are priced according to their population-level health impact through a transparent, replicable process, distinguishing this from other arrangements loosely labeled as value-based that may not align drug prices with clinical benefit.